Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
Summary
Insilico Medicine and Suzhou Ribo Life Science announced a strategic collaboration to combine Insilico's Pharma.AI platform and LifeStar 2 automated laboratory with Ribo's oligonucleotide therapeutics expertise. The partners aim to create end-to-end AI-guided workflows to speed target identification, candidate generation, and experimental validation for siRNA and other oligonucleotide modalities. Insilico highlights recent upgrades to Pharma.AI and LifeStar 2 high-throughput services, while Ribo expects the tie-up to boost efficiency and certainty across its drug development pipeline. Both companies framed the agreement as a broad expansion of prior experimental services into a deeper, strategic cooperation to accelerate clinical-stage programs.
Classifications
AskAI Classifications
LabelsLinked Companies
